216 related articles for article (PubMed ID: 11896285)
1. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature.
Ginsberg G; Hattis D; Sonawane B; Russ A; Banati P; Kozlak M; Smolenski S; Goble R
Toxicol Sci; 2002 Apr; 66(2):185-200. PubMed ID: 11896285
[TBL] [Abstract][Full Text] [Related]
2. Differences in pharmacokinetics between children and adults--II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling.
Hattis D; Ginsberg G; Sonawane B; Smolenski S; Russ A; Kozlak M; Goble R
Risk Anal; 2003 Feb; 23(1):117-42. PubMed ID: 12635728
[TBL] [Abstract][Full Text] [Related]
3. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
4. Pediatric pharmacokinetic data: implications for environmental risk assessment for children.
Ginsberg G; Hattis D; Miller R; Sonawane B
Pediatrics; 2004 Apr; 113(4 Suppl):973-83. PubMed ID: 15060190
[TBL] [Abstract][Full Text] [Related]
5. Incorporating children's toxicokinetics into a risk framework.
Ginsberg G; Slikker W; Bruckner J; Sonawane B
Environ Health Perspect; 2004 Feb; 112(2):272-83. PubMed ID: 14754583
[TBL] [Abstract][Full Text] [Related]
6. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.
Ginsberg G; Hattis D; Russ A; Sonawane B
J Toxicol Environ Health A; 2004 Feb; 67(4):297-329. PubMed ID: 14713563
[TBL] [Abstract][Full Text] [Related]
8. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants.
Ginsberg G; Hattis D; Sonawane B
Toxicol Appl Pharmacol; 2004 Jul; 198(2):164-83. PubMed ID: 15236952
[TBL] [Abstract][Full Text] [Related]
9. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants.
DeWoskin RS; Thompson CM
Regul Toxicol Pharmacol; 2008 Jun; 51(1):66-86. PubMed ID: 18433959
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
Clewell HJ; Gentry PR; Covington TR; Sarangapani R; Teeguarden JG
Toxicol Sci; 2004 Jun; 79(2):381-93. PubMed ID: 15056818
[TBL] [Abstract][Full Text] [Related]
11. Options for incorporating children's inhaled dose into human health risk assessment.
Ginsberg G; Foos B; Dzubow RB; Firestone M
Inhal Toxicol; 2010 Jul; 22(8):627-47. PubMed ID: 20540622
[TBL] [Abstract][Full Text] [Related]
12. Optimizing pediatric dosing: a developmental pharmacologic approach.
Anderson GD; Lynn AM
Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
[TBL] [Abstract][Full Text] [Related]
15. Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences.
Walker K; Hattis D; Russ A; Sonawane B; Ginsberg G
J Toxicol Environ Health A; 2007 Dec; 70(24):2033-55. PubMed ID: 18049993
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
17. PK-DB: pharmacokinetics database for individualized and stratified computational modeling.
Grzegorzewski J; Brandhorst J; Green K; Eleftheriadou D; Duport Y; Barthorscht F; Köller A; Ke DYJ; De Angelis S; König M
Nucleic Acids Res; 2021 Jan; 49(D1):D1358-D1364. PubMed ID: 33151297
[TBL] [Abstract][Full Text] [Related]
18. Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report.
Bruckner JV
Regul Toxicol Pharmacol; 2000 Jun; 31(3):280-5. PubMed ID: 10915586
[TBL] [Abstract][Full Text] [Related]
19. Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.
Strougo A; Yassen A; Monnereau C; Danhof M; Freijer J
J Clin Pharmacol; 2014 Sep; 54(9):1006-15. PubMed ID: 24676942
[TBL] [Abstract][Full Text] [Related]
20. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).
Besunder JB; Reed MD; Blumer JL
Clin Pharmacokinet; 1988 Apr; 14(4):189-216. PubMed ID: 3292100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
